Cholangiocarcinoma—evolving concepts and therapeutic strategies
SI Ilyas, SA Khan, CL Hallemeier, RK Kelley… - Nature reviews Clinical …, 2018 - nature.com
Cholangiocarcinoma is a disease entity comprising diverse epithelial tumours with features
of cholangiocyte differentiation: cholangiocarcinomas are categorized according to …
of cholangiocyte differentiation: cholangiocarcinomas are categorized according to …
New horizons for precision medicine in biliary tract cancers
JW Valle, A Lamarca, L Goyal, J Barriuso, AX Zhu - Cancer discovery, 2017 - AACR
Biliary tract cancers (BTC), including cholangiocarcinoma and gallbladder cancer, are poor-
prognosis and low-incidence cancers, although the incidence of intrahepatic …
prognosis and low-incidence cancers, although the incidence of intrahepatic …
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre …
J Fangusaro, A Onar-Thomas, TY Poussaint… - The lancet …, 2019 - thelancet.com
Background Paediatric low-grade glioma is the most common CNS tumour of childhood.
Although overall survival is good, disease often recurs. No single universally accepted …
Although overall survival is good, disease often recurs. No single universally accepted …
[HTML][HTML] Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
Cholangiocarcinoma (CCA) comprises a heterogeneous group of cancers with pathologic
features of biliary tract differentiation, and is presumed to arise from the intra-or extrahepatic …
features of biliary tract differentiation, and is presumed to arise from the intra-or extrahepatic …
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours
in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive …
in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive …
Overview of current targeted therapy in gallbladder cancer
X Song, Y Hu, Y Li, R Shao, F Liu, Y Liu - Signal Transduction and …, 2020 - nature.com
Gallbladder cancer (GBC) is rare, but is the most malignant type of biliary tract tumor.
Unfortunately, only a small population of cancer patients is acceptable for the surgical …
Unfortunately, only a small population of cancer patients is acceptable for the surgical …
The MAPK pathway across different malignancies: a new perspective
M Burotto, VL Chiou, JM Lee, EC Kohn - Cancer, 2014 - Wiley Online Library
The mitogen‐activated protein kinase/extracellular signal‐regulated (MAPK/ERK) pathway
is activated by upstream genomic events and/or activation of multiple signaling events in …
is activated by upstream genomic events and/or activation of multiple signaling events in …
Gallbladder cancer in the 21st century
Gallbladder cancer (GBC) is an uncommon disease in the majority of the world despite
being the most common and aggressive malignancy of the biliary tree. Early diagnosis is …
being the most common and aggressive malignancy of the biliary tree. Early diagnosis is …
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
Background Effective treatments for patients with cholangiocarcinoma after progression on
gemcitabine-based chemotherapy are urgently needed. Mutations in the BRAF gene have …
gemcitabine-based chemotherapy are urgently needed. Mutations in the BRAF gene have …
Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers
M Yarchoan, L Cope, AN Ruggieri… - The Journal of …, 2021 - Am Soc Clin Investig
BACKGROUND MEK inhibitors have limited activity in biliary tract cancers (BTCs) as
monotherapy but are hypothesized to enhance responses to programmed death ligand 1 …
monotherapy but are hypothesized to enhance responses to programmed death ligand 1 …